The MTHFR 677TT and 677CT/1298AC genotypes in Cypriot patients may be predisposing to hypertensive nephrosclerosis and chronic renal failure

International Angiology

Volumn 24, Issue 3, 2005, Pages 287-294

  Koupepidou, P ^a   Deltas, C ^a,b   Christofides, T C ^a   Athanasiou, Y ^c   Zouvani, I ^c   Pierides, Alkis ^c,d  

^a UNIVERSITY OF CYPRUS   (Cyprus)

^b CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^c NICOSIA GENERAL HOSPITAL   (Cyprus)

^d NONE   (Cyprus)

Author keywords

C677T and A1298C genotypes; Chronic kidney failure; Hypertension; MTHFR gene; Nephrosclerosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ADULT; AGAR GEL ELECTROPHORESIS; AGED; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CAUCASIAN; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CYPRUS; DIABETIC NEPHROPATHY; ESSENTIAL HYPERTENSION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE; GREECE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPOTHESIS; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT HYPERTENSION; MUTATIONAL ANALYSIS; NEPHROSCLEROSIS; POLYMERASE CHAIN REACTION; PREVALENCE; RESTRICTION MAPPING; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYPRUS; DNA PRIMERS; ELECTROPHORESIS, AGAR GEL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GREECE; HOMOZYGOTE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION, MISSENSE; NEPHROSCLEROSIS; POLYMERASE CHAIN REACTION; SEROEPIDEMIOLOGIC STUDIES;

EID: 27744533784     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Makris M. Hyperhomocysteinemia and thrombosis. Clin Lab Haem 2000;22:133-43
2. Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell Mol Life Sci 2004:61:470-87.
3. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202-6.
4. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG; MTHFR Studies Collaboration Group. MTHFR 677C->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002:288:2023-31.
5. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
6. Soinio M, Marniemi J. Laakso M, Lehto S, Ronnemaa T. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med 2004:140:94-100.
7. Moczulski D, Fojcik H, Zukowska-Szczechowska E, Szydlowska I, Grzeszczak W. Effects of the C677T and A1298C polymorphisms of the MTHFR gene on the genetic predisposition for diabetic nephropathy. Nephrol Dial Transplant 2003:18:1535-40.
8. Hsu H, Churg J. The ultrastructure of mucoid "onion-skin" intimal lesions in malignant nephrosclerosis. Am J Pathol 1980;99:67-80.
9. Mountokalakis T. The renal consequences of arterial hypertension. Kidney Int 1997;51:1639-53.
10. Weisstuch JM, Dworkin LD. Does essential hypertension cause end-stage renal disease? Kidney Int Suppl 1992; 36:S33-7.
11. Ruilope LM, Alcazar JM, Rodicio JL. Renal consequences of arterial hypertension. J Hypertens Suppl 1992;10: S85-90.
12. Innes A, Johnston PA, Morgan AG, Davison AM, Burden RP. Clinical features of benign hypertensive nephrosclerosis at time of renal biopsy. Q J Med 1993;86:271-5.
13. Zucchelli P, Zuccala A. Primary hypertension: how does it cause renal failure? Nephrol Dial Transplant 1994;9: 223-5.
14. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25:305-13.
15. Hajjar I, Kotchen TA. Trends in the prevalence, awareness, treatment and control of hypertension in the United States, 1998-2000 JAMA 2003;290:196-206.
16. Zarif L, Covie A, Iyengar S, Sehgal AR, Sedor JR. Schelling JR. Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant 2000;11:1801-7.
17. Caetano ER, Zatt R, Saldanha LB, Praxedes JN Hypertensive nephrosclerosis as a relevant cause of chronic renal failure. Hypertension 2001:2:171-6.
18. Perera GA. Hypertensive vascular disease; description and natural history. J Chronic Dis 1955;1:33-42.
19. Farrington K, Levison DA, Greenwood RN, Cattell WR, Baker LR. Renal biopsy in patients with unexplained renal impairment and normal kidney size. Q J Med 1989;70: 221-33.
20. Malangone JM, Abuelo JG, Pezzullo JC, Lund K, McGloin CA. Clinical and laboratory features of patients with chronic renal disease at the start of dialysis. Clin Nephrol 1989;31:77-87.
21. Pillay VK, Wang F, Gandhi VC, Lee HJ, Dunea G. Uraemia from benign hypertension. S Afr Med J 1974;48:953-6.
22. Motulsky AG. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects and folic acid. Am J Hum Gen 1996;58:17-20.
23. Angelopoulou K, Nicolaides A, Constantinou Deltas C. Prevalence of genetic mutations that predispose to thrombophilia in a Greek Cypriot population. Clin Appl Thromb Hemost 2000;6:104-7.
24. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
25. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
26. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998;62:1044-51.
27. Van der Put NMJ, Blom HJ. Reply to Donnelly. Am J Hum Genet 2000;66:744-5.
28. Sunder-Plassmann G, Fodinger M. Genetic determinants of the homocysteine level. Kidney Int Suppl 2003;84: S141-4.
29. Isotalo PA, Wells GA Donnely G. Neonatal and fetal MTHFR genetic polymorphisms: an examination of C677T and A1298C mutations. Am J Hum Genet 2000;67:986-90.
30. Caulfield M, Munroe P, Pembroke J, Samani N, Dominiczak A, Brown M et al.; MRC British Genetics of Hypertension Study. Genome-wide mapping of human loci for essential hypertension. Lancet 2003;361:2118-23.
31. Garcia EA, Newhouse S, Caulfield MJ, Munroe PB. Genes and hypertension. Curr Pharm Des 2003;9:1679-89
32. Porto PI, Garcia SI, Dieuzeide G, Gonzalez C, Pirola CJ. Renin-angiotensin-aldosterone system loci and multilocus interactions in young-onset essential hypertension. Clin Exp Hypertens 2003;25:117-30.
33. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med 2003;139:761-76.
34. Kahleova R, Palyzova D, Zvara K, Zvarova J, Hrach K, Novakova I et al. Essential hypertension in adolescents: association with insulin resistance and with metabolism of homocysteine and vitamins. Am J Hypertens 2002; 15(10 Pt 1):857-64.
35. Makris T, Krespi P, Hatzizacharias H et al. The incidence of MTHFR gene mutation among hypertensives: Its association with major cardiovascular events. J Hypertens 2004;22:S73.
36. Ritz E, McClellan WM. Overview: increased cardiovascular risk in patients with minor renal dysfunction: An emerging issue with far-reaching consequences. J Am Soc Nephrol 2004;15:513-6.
37. Segura J, Campo C, Gil P, Roldan C, Vigil L, Rodicio JL et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004;15:1616-22.